Following a feud with activist investor Deep Track Capital in the first half of 2025, vaccine developer Dynavax Technologies ...

Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...

Pharma's end-of-year dealmaking flurry is not showing signs of slowing, as, now, two Japanese drugmakers have joined the ...

In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Andrew Willett discussed the path that led him to Lundbeck and ...

As biopharma and healthcare companies face a rapidly shifting regulatory environment, marketing and advisory firm Avalere ...

Medtronic initially secured FDA clearance for the MiniMed 780G pump for people with Type 1 diabetes in early 2023. This past ...

In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...